Novavax vaccine is 90 percent effective against COVID-19

On Monday, Novavax released positive results from clinical trials. Its vaccine candidate showed 90.4 percent efficacy against COVID-19 infection, including 100 percent efficacy against moderate and severe disease. By the end of September 2021, the company is slated to produce 100 million doses.